Clinical Trials Browser

Phase 2 × Active not recruiting × ribociclib × Clear all

NCT03008408 2026-05-22

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2 Active not recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT05296746 2026-05-14

RIBOLARIS

Phase 2 Active not recruiting

Breast Neoplasms

NCT02934568 2026-04-16

Ribociclib (LEE011) Rollover Study for Continued Access

Phase 2 Active not recruiting

Other solid neoplasm

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

Phase 2 Active not recruiting

51 enrolled 19 charts

Cystadenocarcinoma, Serous

NCT03285412 2025-12-22

LEADER

Phase 2 Active not recruiting

Breast Neoplasms

NCT03283384 2025-09-19

NEOLBC

Phase 2 Active not recruiting

Breast Neoplasms

NCT05625087 2025-08-20

SAFIR 03

Phase 2 Active not recruiting

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

Phase 2 Active not recruiting

Breast Neoplasms